Baseline organ dysfunction precluding standard cisplatin-based chemoradiation or pembroli...

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`RF-HNSCC-ORGAN-DYSFUNCTION`
Type	Red flag
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-HNSCC`
Sources	`SRC-ESMO-HNSCC-2020` `SRC-NCCN-HNSCC-2025`

Red Flag Origin

Definition	Baseline organ dysfunction precluding standard cisplatin-based chemoradiation or pembrolizumab + 5-FU + cisplatin / cetuximab in head and neck squamous cell carcinoma: CrCl <60 mL/min (cisplatin contraindicated at full dose, switch to carboplatin or cetuximab), hearing loss / ototoxicity baseline (cisplatin contraindicated), LVEF <50% (5-FU cardiac risk), bilirubin >3× ULN (taxane / 5-FU metabolism), or severe peripheral neuropathy (cisplatin + taxane contraindicated).
Clinical direction	de-escalate
Category	organ-dysfunction

Trigger Logic

{
  "any_of": [
    {
      "comparator": "<",
      "finding": "creatinine_clearance_ml_min",
      "threshold": 60
    },
    {
      "finding": "baseline_ototoxicity",
      "value": true
    },
    {
      "comparator": "<",
      "finding": "lvef_percent",
      "threshold": 50
    },
    {
      "comparator": ">=",
      "finding": "bilirubin_ratio_to_uln",
      "threshold": 3
    },
    {
      "comparator": ">",
      "finding": "peripheral_neuropathy_grade",
      "threshold": 2
    }
  ],
  "type": "lab_value"
}

Notes

Cisplatin-based CRT is the curative-intent standard (Intergroup 0099, TAX 324, EORTC 24891) but ~30% of HNSCC patients are cisplatin- ineligible at presentation due to age + organ dysfunction. CrCl <60: switch to carboplatin (RTOG 81-17 lower local control but acceptable) or cetuximab + RT (Bonner trial — less effective than cisplatin per RTOG 1016 / De-ESCALaTE post hoc but tolerated in cisplatin-ineligible). Baseline hearing loss is gating for cisplatin — high cumulative ototoxicity rate (40% Gr2+) compounds. LVEF <50: 5-FU + cisplatin triplet risky — pembrolizumab monotherapy (KEYNOTE-048 if PD-L1 CPS ≥1) is alternative for R/M setting.

Used By

Indications

IND-HNSCC-RM-1L-EXTREME - IND-HNSCC-RM-1L-EXTREME
IND-HNSCC-RM-1L-PEMBRO-CHEMO - IND-HNSCC-RM-1L-PEMBRO-CHEMO
IND-HNSCC-RM-1L-PEMBRO-MONO-CPS-HIGH - IND-HNSCC-RM-1L-PEMBRO-MONO-CPS-HIGH
IND-HNSCC-RM-2L-NIVOLUMAB - IND-HNSCC-RM-2L-NIVOLUMAB
IND-HNSCC-RM-2L-PEMBROLIZUMAB - IND-HNSCC-RM-2L-PEMBROLIZUMAB